Predicting Alzheimer's Disease Using Combined Imaging-Whole Genome SNP Data

Area of Science:

• Neuroscience
• Genetics
• Medical Imaging

Background:

• Alzheimer's disease (AD) poses a significant public health challenge, necessitating early prognostic biomarkers.
• Identifying individuals at risk for AD progression is critical for timely intervention.
• Mild cognitive impairment (MCI) is an early stage often preceding AD.

Purpose of the Study:

• To evaluate the predictive value of combined whole genome single nucleotide polymorphism (SNP) data and high-dimensional brain imaging data for AD onset.
• To determine if integrating imaging and genetic data enhances risk prediction in MCI patients.

Main Methods:

• Utilized data from 343 MCI participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI-1).
• Extracted high-dimensional MRI data (93 brain regions, hippocampal subregions) and whole genome data (504,095 SNPs).
• Followed participants for 48 months, monitoring progression from MCI to AD (150 participants).

Main Results:

• The combined model using brain imaging and whole genome data demonstrated substantially superior predictive performance compared to standard models.
• Integration of imaging and genetic markers significantly improved the prediction of time to AD onset over 48 months.
• The findings highlight the synergistic effect of multimodal data in prognostic modeling.

Conclusions:

• Combined neuroimaging and whole genome data serve as promising prognostic markers for predicting AD development in individuals with mild memory impairment.
• This multimodal approach offers a more robust strategy for identifying at-risk populations.
• Further validation of these combined markers could aid in early diagnosis and therapeutic strategies for AD.